South Africa carries the largest human immunodeficiency virus (HIV) burden globally with an estimated 7.2 million people with HIV (PWH) at the end of 2017 and approximately 4 million people on antiretroviral treatment (ART) \[[@CIT0001]\]. Despite South Africa hosting the largest HIV treatment program in the world, with universal ART eligibility, overall treatment coverage is only 56%. Most PWH on treatment receive a nonnucleoside reverse-transcriptase (NNRTI)-based first-line regimen, whereas those who fail NNRTI-based regimes are switched to a protease inhibitor (PI)-containing regimen. In the public sector, third-line drugs such as ritonavir-boosted darunavir (DRV/r) and raltegravir (RAL) have been available since May 2013, and dolutegravir (DTG) has been available since July 2016. Third-line ART (TLART) in the public sector is accessed through a centralized national committee. Individuals are eligible if they have been exposed to a PI-based regimen for at least 1 year, present with virologic failure despite adherence optimization, and have genotypic evidence of PI resistance. A TLART application is then submitted to the national TLART committee that assesses eligibility and makes a regimen recommendation on a case-by-case basis. All patients eligible for TLART receive DRV/r in combination with a dual nucleoside reverse-transcriptase backbone, with or without an integrase strand transfer inhibitor (INSTI), based on the genotypic profile. The number of patients in need of TLART in South Africa is estimated to be 2800, based on the assumption that 170 000 patients receive a PI-based regimen, 10% of whom are assumed to have virological failure with a 16% prevalence of major PI mutations as seen in a national survey \[[@CIT0002]\]. However, as of October 2018, only 1606 patients were switched to a TLART regimen, including 1084 patients on an INSTI-based regimen (650 on DTG and 434 on RAL) (TLART committee, written personal communication, 10 May 2019.

Evidence of TLART outcomes in low- and middle-income countries are limited. In Botswana, 80% of 93 highly treatment-experienced patients suppressed on a DTG-based salvage regimen \[[@CIT0003]\]. In South Africa 78% to 83% of patients obtain virological suppression on TLART \[[@CIT0004]\]. A study from Uganda reported prevalence of INSTI resistance in RAL-based third-line failures at 47% (24 of 51) with RAL and/or elvitegravir (EVG) resistance and 4% (2 of 51) with DTG resistance \[[@CIT0007]\]. Whereas an Argentinian survey reported 72% of patients (41 of 57) on RAL-based salvage ART presented with RAL and/or EVG resistance and 32% presented with with intermediate (29%) to high-level (2%) DTG cross-resistance \[[@CIT0008]\], data from Botswana show that only 4 of 20 (20%) patients failing DTG-based salvage regimens had INSTI resistance \[[@CIT0003]\].

This study aims to assess INSTI resistance among patients failing INSTI-based TLART in the South African public sector.

MATERIALS AND METHODS {#s1}
=====================

We conducted a retrospective analysis of all HIV drug resistance (HIVDR) data obtained from patients who had an INSTI genotyping test request between of January 1, 2015 and of October 31, 2018 at any of the National Health Laboratory Service facilities. For patients with more than 1 INSTI genotype request, only the most recent sequence was included. Demographic and clinical information such as age, ART regimen, and time on INSTI regimen were collected from paper-based laboratory request forms. The latest viral load measurements were extracted from the electronic laboratory information system. A patient file review to obtain detailed treatment regimen information was not permitted due to ethical restrictions.

Integrase strand transfer inhibitor resistance testing was conducted at Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg or Tygerberg Hospital, Stellenbosch. Each laboratory generated integrase sequences using their respective validated, population-based, in-house genotyping method \[[@CIT0009]\]. Both laboratories successfully participated in ≥1 international external quality assurance panel per year. The Stanford HIVdb v8.7 tool (<http://sierra2.stanford.edu/sierra/servlet/JSierra>) was used to identify HIVDR mutations and generate resistance profiles and categorized as susceptible, intermediate-level, or high-level resistance. Sequences were aligned using MEGA and a phylogenetic tree constructed to detect cross-contamination and omit duplicates from analyses. Subtyping was performed using the Rega HIV subtyping tool v3.0 (<http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/>).

The *pol* nucleotide sequences were submitted to GenBank using Bankit (<https://www.ncbi.nlm.nih.gov/WebSub/>; accession numbers [MK899435](MK899435) to [MK899477](MK899477)).

Statistical analyses were performed using GraphPad Prism 8. Two-sided Fisher's exact tests were used to compare mutation prevalence between groups, considering *P* \< .05 as statistically significant. Confidence intervals (CIs) at 95% were calculated using the modified Wald method.

This study was conducted with Ethical clearance by the Research on Human Subjects (Medical) Committee at the University of the Witwatersrand (Clearance Number M1802227). Due to the retrospective nature of this study, no informed consent was obtained from the patients. This is in line with the Research on Human Subjects (Medical) Committee policy, which states that informed consent is not required for this type of study and hence a waiver was granted.

RESULTS {#s2}
=======

A total of 48 integrase sequences were submitted for review, 5 of which were excluded due to multiple sampling, leaving a cohort of 43 unique patients for final analysis. Integrase resistance was therefore assessed in 43 of 1084 patients on INSTI regimens in South Africa (4%) INSTI-exposed patients. Most integrase sequences, 98% (42 of 43), were classified as subtype C, 1 sequence belonged to subtype G. The cohort comprised 51% males, had a median age of 41 years (interquartile range \[IQR\], 26--48), and included 2 children (3 and 5 years old) and 6 adolescents. The median HIV viral load at time of HIVDR testing was 4.6 log copies/mL (IQR, 3.8--5.2). Most patients had been exposed to RAL-based regimens (79%, n = 34), including 3 patients who had been exposed to RAL in the past but were not receiving any INSTI at time of HIVDR testing. Four (9%) patients were exposed to DTG. Five cases (12%) had no treatment regimen available at time of testing ([Figure 1](#F1){ref-type="fig"}). Most patients (58%, n = 25) received a combination of an INSTI with DRV/r, whereas 10 patients (23%) were exposed to ritonavir-boosted lopinavir (LPV/r); 1 patient received ritonavir-boosted atazanavir, and 5 patients (12%) received an INSTI regimen without a boosted PI. Duration of INSTI exposure was known for 27 cases (63%) with a median of 25 months (IQR, 14--34).

![Flow-chart of patients failing integrase strand transfer inhibitor (INSTI)-based treatment in South Africa. \*, For patients with ≥1 genotype request, only the most recent result was included. ^¥^, Three of 34 patients had been exposed to raltegravir (RAL) in the past but have no record on INSTI exposure at time of genotyping. ART, antiretroviral treatment; DTG, dolutegravir; EVG, elvitegravir.](ofz377f0001){#F1}

Resistance to first-generation INSTIs (RAL and EVG) was detected in 51% (22 of 43; 95% CI, 37%--65%) of all cases. All 22 cases presented with high-level resistance to RAL, whereas 9 and 12 cases showed intermediate and high-level resistance to EVG, respectively. Resistance to first-generation INSTIs was detected in 20 of 34 (59%; 95% CI, 42%--74%) in the RAL-exposed group (*P* = .6473).

Three patients (7%) presented with intermediate to high-level resistance to DTG ([Table 1](#T1){ref-type="table"}). All 3 patients with DTG resistance also showed reduced activity to their boosted PI, but none of these patients had lost complete activity to the respective PIs ([Table 1](#T1){ref-type="table"}). All 3 patients had been on ART for a prolonged period. Patient 25 was initiated on d4T-3TC-NVP and remained on this regimen for 8 years before being switched to a dual regimen of RAL and LPV/r (5 years). It is unknown why this patient only received a dual regimen. Patient 9 had been exposed to d4T-3TC-EFV and TDF-3TC-EFV for an unknown period before being switched to ABC-3TC-DRV/r-RAL (2 years). Patient 8 started on TDF-3TC-NVP (6 years), after which NVP was replaced by LPV/r (4 years); eventually the patient was changed to TDF-3TC-DRV/r-DTG for 22 months before genotyping. Overall, complete loss of boosted PIs was only seen in 8% (2 of 25) of DRV/r-exposed patients and 50% (n = 5 of 10) of the LPV/r-exposed patients.

###### 

Demographic, Clinical, and Resistance Profiles for Patients With Integrase Resistance Testing

  Patient   Age   RAL/DTG Exposure   Time on INSTIs (Months)   ART Regimen at Time of HIVDR Testing   HIVVL (Copies/mL)   RAL   EVG   DTG   ATV/r   DRV/r   LPV/r
  --------- ----- ------------------ ------------------------- -------------------------------------- ------------------- ----- ----- ----- ------- ------- -------
  9         52    RAL                24                        ABC-3TC-DRV/r-RAL                      2430                HLR   HLR   HLR   HLR     IR      HLR
  25        35    RAL                60                        LPV/r-RAL                              23 233              HLR   HLR   IR    IR      S       IR
  1         17    RAL                25                        TDF-FTC-DRV/r-ETR-RAL                  3459                HLR   HLR   S     IR      IR      HLR
  14        43    RAL                48                        TDF-3TC-RAL                            3070                HLR   HLR   S     IR      IR      HLR
  11        52    RAL                69                        DRV/r-RAL                              270 252             HLR   HLR   S     *NA*    *NA*    *NA*
  6         51    RAL                36                        TDF-3TC-DRV/r-RAL                      27 500              HLR   HLR   S     HLR     IR      HLR
  26        46    RAL                Unknown                   LPV/r-RAL                              2316                HLR   HLR   S     S       S       S
  4         31    RAL                5                         d4T-3TC-DRV/r-RAL                      58 200              HLR   HLR   S     HLR     IR      HLR
  12        43    RAL                12                        TDF-3TC-DRV/r-RAL                      159 000             HLR   HLR   S     IR      IR      HLR
  10        61    RAL                20                        3TC-LPV/r-RAL                          92 800              HLR   HLR   S     HLR     S       HLR
  16        45    RAL                32                        TDF-FTC-DRV/r-RAL                      13 000              HLR   HLR   S     S       S       S
  42        12    RAL                Unknown                   ABC-3TC-DRV/r-RAL                      1843                HLR   IR    S     HLR     IR      HLR
  18        44    RAL                23                        TDF-3TC-RAL                            778 000             HLR   IR    S     S       S       S
  2         47    RAL                18                        TDF-3TC-DRV/r-RAL                      27 727              HLR   IR    S     HLR     S       HLR
  7         20    RAL                22                        LPV/r-RAL                              211 000             HLR   IR    S     HLR     IR      HLR
  27        51    RAL                25                        TDF-LPV/r-RAL                          1 030 000           HLR   IR    S     IR      IR      HLR
  13        35    RAL                34                        ETR- RAL-DRV/r                         190 000             HLR   IR    S     HLR     IR      HLR
  32        52    RAL                Unknown                   AZT-3TC-DRV/r-RAL                      7190                HLR   IR    S     HLR     HLR     HLR
  43        45    RAL                Unknown                   AZT-3TC-RAL                            159 000             HLR   IR    S     HLR     S       S
  40        34    RAL                Unknown                   AZT-3TC-RAL                            67 816              HLR   S     S     S       S       S
  24^a^     45    RAL                3                         AZT-3TC-LPV/r(*AZT-LPV/r-RAL)*         2520                S     S     S     S       S       S
  37        35    RAL                Unknown                   ETR-DRV/r-RAL                          9337                S     S     S     S       S       S
  29        14    RAL                13                        AZT-3TC-DRV/r-RAL                      42 900              S     S     S     S       S       S
  5^a^      58    RAL                25                        ABC-3TC-ATZ/r(*TDF-3TC-RAL-DRV/r)*     386 000             S     S     S     S       S       S
  28        18    RAL                27                        AZT-3TC-DRV/r-RAL                      1140                S     S     S     S       S       S
  17        39    RAL                33                        ABC-TDF-3TC-DRV/r-RAL                  64 200              S     S     S     IR      IR      HLR
  19        54    RAL                42                        TDF-FTC-DRV/r-RAL                      140 714             S     S     S     HLR     IR      HLR
  22        37    RAL                53                        AZT-3TC-TDF-DRV/r-RAL                  6990                S     S     S     HLR     HLR     HLR
  31^a^     50    RAL                70                        ABC-3TC-LPV/r(*TDF-FTC-LPV/r-RAL)*     1 370 000           S     S     S     HLR     IR      HLR
  20        21    RAL                Unknown                   TDF-3TC-ETR-DRV/r-RAL                  14 900              S     S     S     S       S       S
  41        16    RAL                Unknown                   3TC-DRV/r-RAL                          30 663              S     S     S     *NA*    *NA*    *NA*
  33        12    RAL                Unknown                   ETR-DRV/r-RAL                          2530                S     S     S     HLR     IR      HLR
  34        10    RAL                Unknown                   AZT-3TC-DRV/r-RAL                      868                 S     S     S     IR      S       IR
  38        3     RAL                Unknown                   ABC-3TC-LPV/r-RAL                      88 821              S     S     S     S       S       S
  8         38    DTG                22                        TDF-3TC-DRV/r-DTG                      311 000             HLR   HLR   IR    IR      IR      HLR
  15        45    DTG                4                         TDF-3TC-DRV/r-DTG                      39 400              S     S     S     IR      IR      HLR
  30        43    DTG                10                        AZT-3TC-DTG                            6500                S     S     S     S       S       S
  39        31    DTG                1                         ABC-3TC-ATV/r-DTG                      117 274             S     S     S     S       S       S
  35        55    Unknown            Unknown                   Unknown                                429 241             HLR   IR    S     HLR     HLR     HLR
  3         57    Unknown            Unknown                   AZT-EFV-LPV/r                          222 604             S     S     S     S       S       S
  21        5     Unknown            Unknown                   Unknown                                6990                S     S     S     IR      S       IR
  23        41    Unknown            Unknown                   AZT-3TC-LPV/r                          19 400              S     S     S     IR      S       HLR
  36        39    Unknown            Unknown                   TDF-FTC-DRV/r                          139 609             S     S     S     HLR     IR      HLR

Abbreviations: ABC, abacavir; ART, antiretroviral treatment; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; d4T, stavudine; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; ETR, etravirine; EVG, elvitegravir; FTC, emtricitabine; HIV, human immunodeficiency virus; HIVDR, HIV drug resistance; HIVVL, HIV viral load; HLR, high-level resistance; INSTIs, integrase strand transfer inhibitors; IR, intermediate resistance; LPV/r, ritonavir-boosted lopinavir; NA, not applicable, no protease and reverse-transcriptase genotype available; RAL, raltegravir; S, susceptible; TDF, tenofovir; 3TC, lamivudine.

^a^Three patients were not receiving an INSTI at time of genotyping, but their previous regimen (in italics) indicate exposure to INSTI.

The most common major INSTI mutations were Y143C/R/H (n = 12) and N155H (n = 9); the accessory T97A mutation was detected in 13 cases. The complete integrase, protease, and reverse-transcriptase mutation profile is presented in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Only 4 patients in the cohort had recorded exposure to DTG, and 3 of them presented without any INSTI mutations after 1, 4, and 10 months of DTG-exposure, respectively. The fourth patient presented with intermediate resistance to DTG after 22 months of DTG exposure ([Table 1](#T1){ref-type="table"}).

Discussion {#s3}
==========

This retrospective study provides important insights into the INSTI resistance profiles in patients failing INSTI-based TLART in the South African public sector. The presence of INSTI resistance is common in patients failing RAL-based regimens (59%) after a median of only 25 months of RAL-exposure, confirming the low genetic barrier of first-generation INSTIs. These results are lower than those observed in Argentina where 72% of heavily treated patients presented with RAL and/or EVG resistance after a median of 22.5 months of RAL exposure \[[@CIT0008]\]. Our findings are more similar to those from a Ugandan cohort of 51 patients failing RAL-based TLART where 47% of patients presented with RAL and/or EVG resistance \[[@CIT0007]\]. The prevalence of HIV-1 subtypes differs globally and among studies reporting INSTI resistance: HIV-1 subtype B/F and B predominated in the Argentinian cohort versus A, D, and A/D in Uganda and subtype C in our study. Human immunodeficiency virus-1 subtype may influence INSTI development. However, our study was not able to establish subtype associations due to the small sample and many possible confounders such as regional differences in treatment regimens, virological failure monitoring, and concomitant medication. Therefore, it is not known whether the higher frequency of multiple INSTI mutations in the Argentinian cohort (49%), compared with 40% in our study, might indicate a subtype association. In our study, all patients with only RAL/EVG resistance presented with a single major INSTI mutation with (n = 16) or without (n = 5) accessory INSTI mutations. In contrast, the 3 patients with DTG resistance presented with at least 2 major INSTI mutations, indicating that accumulation of INSTI mutations should be avoided. The most common mutations in RAL-exposed patients were Y143C/R/H and N155H (29% each), which are known to be common in RAL-exposed patients \[[@CIT0010]\]. The third signature RAL mutation, Q148R, which is commonly observed in subtype B, was only observed once in this study. The R263K mutation was not observed in our cohort, which was also reported by Argentinian and Ugandan studies \[[@CIT0007], [@CIT0008]\]. Cross-resistance to DTG remains limited to 6% in RAL-exposed individuals, which is also consistent with the Ugandan findings (4%) \[[@CIT0007]\], but this is substantially lower compared with the findings from the Argentinian cohort (32%), where poor adherence was reported by most patients \[[@CIT0008]\].

Our results suggest that most patients failing RAL regimens can still benefit from a DTG-based regimen, provided limited accumulation of INSTI mutations. The Viking 3 study showed that 69% of patients, who previously failed RAL-based ART with resistance mutations, obtained virological suppression at week 24 on DTG-based regimens, administering DTG 50 mg bid. In addition, an Italian, real-life cohort analyzed virological outcomes in RAL/EVG-exposed patients who switched to DTG-salvage regimens \[[@CIT0011]\]. None of the 79 patients who remained on DTG after a median of 18 months in this study experienced virological failure at the end of the follow-up period. Despite a favorable prognosis of viral suppression for RAL-experienced patients on DTG-regimens, there is concern that those patients who remain on a failing RAL-based regimen are at risk of accumulating multiple INSTI mutations and thereby reducing DTG activity. Appropriate interruption of RAL could prevent accumulation of mutations, hence optimizing the effect of DTG in RAL-exposed patients. The current recommendation from the TLART committee is to administer DTG twice daily in patients with confirmed or suspected INSTI resistance \[[@CIT0012]\].

Although the group of DTG-based failures is very small (n = 4), one of these patients presented with DTG resistance after only 22 months of DTG exposure with multiple mutations: T66A, E138K, Y143R, S147G, Q95K, and T97A. A recent case report from Botswana also described DTG resistance in a highly treatment-experienced, DTG-exposed patient with 5 INSTI mutations (E138K, G140A, S147G, Q148R, T97A) but without R263K \[[@CIT0013]\]. The variability of resistance pathways selected under DTG pressure was also confirmed in various DTG mono or "less-drugs trials", which were reviewed by Blanco et al \[[@CIT0014]\]. The signature DTG mutation R263K was not detected in any of the patients exposed to DTG. This might be due to the small sample size, but it has also been shown that the prevalence of R263K in subtype C might be lower compared with subtype B because this mutation is shown to be more deleterious in subtype C \[[@CIT0015]\].

The study presented is limited by the lack of an accurate measure of the frequency of patients currently failing INSTI-based ART, and subsequently those that are referred for genotyping, in the South African HIV programme, which would permit an estimation of representativeness. However, integrase resistance testing for the public sector is only offered in 2 laboratories; all data from these laboratories were collated to make the study as representative as possible. Treatment history and duration of INSTI exposure were only extracted from drug resistance test request forms, which were limited. Information on treatment adherence was not available; however, these patients are likely to be considered as adherent because intensified adherence counseling is recommended before PI resistance can be confirmed by genotyping. Therefore, these findings are not necessarily generalizable to other populations that might receive INSTI-based regimens in the future. Finally, mutations in the 3'-polypurine tract, which have also been reported to contribute to DTG resistance, were not assessed \[[@CIT0016]\]. Despite these drawbacks, the study provides current analysis of integrase resistance in South Africa.

Conclusions {#s4}
===========

Overall, our findings indicate that patients failing RAL-containing regimens are prone to the development of resistance, albeit limited observed cross-resistance to DTG. Although patients with pre-existing RAL mutations are likely to respond well to DTG-based salvage regimens, it is of concern that further accumulation of mutations may lead to DTG resistance. Since July 2016, DTG has been the preferred INSTI for TLART in South Africa. Now that DTG is available in the public sector, we recommend that, unless clinically contraindicated, RAL should be replaced by DTG in all patients on salvage regimens, to prevent potential accumulation of INSTI resistance mutations. The risk of development of resistance under DTG pressure cannot be estimated from this retrospective study; however, it is clear that in the absence of adequately powered prospective controlled studies, surveillance programs should be implemented once DTG is introduced on a larger scale in these settings, particularly because it is being considered for first-line treatment.

Supplementary Data {#s5}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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Click here for additional data file.
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